The British Journal of Rheumatology, Vol 37, 1240-1242, Copyright © 1998 by British Society for Rheumatology
AO Adebajo and MA Hall
An open prospective study using i.v. methylprednisolone in children with
juvenile chronic arthritis (JCA) who had had a systemic exacerbation of
disease is described. Eighteen children aged from 3 to 14 yr and 9 months
(mean 9.7 yr) were treated. Ten patients (55%) had a loss of all systemic
features 1 month after the pulse, and eight (45%) had a reduction in the
active joint count. At this time, five of the patients on oral prednisolone
had achieved a reduction in dosage. Also at 1 month, a reduction in
erythrocyte sedimentation rate was observed in 11 patients (61%) and of
C-reactive protein in 11 of 16 (72%). Altogether, 13 patients (72%) had a
good response, while a further three (16%) went into remission. Our
conclusions are that pulse methylprednisolone provides good short-term
benefit in patients with systemic-onset JCA; no serious side-effects were
noted. Further long- term studies are warranted.
ORIGINAL PAPERS
The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis
Department of Paediatric Rheumatology, Wexham Park Hospital, Slough.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. A. Bell Pharmacotherapy of Juvenile Idiopathic Arthritis Journal of Pharmacy Practice, February 1, 2009; 22(1): 17 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Pascual, F. Allantaz, E. Arce, M. Punaro, and J. Banchereau Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade J. Exp. Med., May 2, 2005; 201(9): 1479 - 1486. [Abstract] [Full Text] [PDF]
|
|